Wellspect Medicare Coverage Positive but Incremental for XRAY's Turnaround

What happened

Wellspect HealthCare, Dentsply Sirona's continence-care segment, announced that its Surity urinary management portfolio may now be covered by traditional Medicare when medically necessary. This milestone expands access to at-home management for severe urinary incontinence, potentially supporting Wellspect's growth, which was the only segment to grow in Q2 2026 (up 3.8% constant currency). However, Wellspect represents only about 10% of Dentsply Sirona's total sales, so the impact on the overall company is limited. The core dental segments (CTS, EDS, OIS) continue to face declines, pricing pressure, and distributor challenges. Therefore, while this news is a positive for one business line, it does not materially alter the investment thesis for XRAY.

Implication

Investors should view this as a modest tailwind for the Wellspect segment, which could help support overall revenue stability but is unlikely to offset the declines in the larger dental segments. The key catalysts for XRAY remain the Q3 2026 CTS growth after distributor expansions and margin improvement without tariff refunds. Until those core issues show clear improvement, the stock's risk-reward remains unfavorable at current levels. The news does not alter the bear-case risks of continued digital pricing pressure and EMEA destocking. Accordingly, we maintain a WAIT rating with no change to the attractive entry point or trim level.

Thesis delta

The thesis remains unchanged: XRAY is a guarded turnaround awaiting proof of recovery in its core dental segments. The Wellspect Medicare announcement is a positive development but does not address the challenges in Connected Technology Solutions, Essential Dental Solutions, and Orthodontic and Implant Solutions. Therefore, we keep our WAIT rating and conviction unchanged.